The 30th European Hematology Association (EHA) Annual Congress will be held from June 12 to 15, 2025, in Milan, Italy. As one of the most influential global events in hematology, this congress will convene experts, scholars, and industry leaders from around the world to explore the latest advances in hematologic disease diagnosis and treatment, and to envision future developments.

Facing complex and evolving challenges in hematologic malignancies and tumor therapies, the GoBroad medical team continues to target unmet patient needs with robust scientific strength and keen clinical insight. At this year’s EHA Congress, the GoBroad team will present 24 research achievements, including 1 oral presentation, 16 poster presentations, and 7 published abstracts. These contributions range from disease mechanism exploration and efficacy validation to innovative drug combinations, precise classification-based treatments, and optimization of therapeutic strategies—once again showcasing China's clinical insights and deep exploration on the international stage.

Oral Presentation

Abstract ID: S262
Title: Anti-CD25 Antibody as an Alternative to Methotrexate for Graft-Versus-Host Disease Prophylaxis Resulted in Better Outcomes in Patients of Chimeric Antigen Receptor-T Cell Therapy Bridging to Transplant
(Anti-CD25 monoclonal antibody replacing MTX for GVHD prevention improves prognosis in CAR-T patients undergoing transplant)

Poster Presentations

#PS1378

Clinical Efficacy Analysis of CAR-T Therapy in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia with Extramedullary Disease

#PS1390
Clinical Analysis of Sequential CAR-T Cell Therapy Combined with Venetoclax, Hypomethylating Agents, and Personalized Targeted Drugs in Elderly Patients with Relapsed/Refractory B-ALL

#PS1920
Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cell Therapy Significantly Improves Progression-Free Survival in Relapsed/Refractory Central Nervous System Lymphoma

#PS2016
Pre-Infusion CD57⁺ CAR-T Cell Frequency and Early Post-Infusion PD-1 Expression Correlate with Clinical Outcomes Following CAR-T Cell Therapy for Hematological Malignancies

#PS2080
Allogeneic Hematopoietic Stem Cell Transplantation for Diamond-Blackfan Anemia: Favorable Outcomes from a Single Center

#PF357
Frequency of Variant ALK Fusions and Prognostic Impact of Clinical and Molecular Features in Chinese Pediatric ALK⁺ Anaplastic Large Cell Lymphoma (ALCL)

#PF391
Excellent Long-Term Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Ph⁺ B-Cell Acute Lymphoblastic Leukemia Patients Failing to Achieve Complete Molecular Remission

#PF395
Improving Lymphopenia and Reducing the Risk of Infection Through the Infusion of CD7 Gene Knock-Out Lymphocytes for R/R T-ALL After CD7 CAR-T Cell Therapy

#PF933
Superior Outcomes of Autologous Transplantation Versus CAR-T Therapy in Relapsed CNS Lymphoma Treated in Complete Remission

#PF938
Safety and Efficacy of Dual-Target CD19/CD20 CAR-T Therapy in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

#PF941
Long-Term Efficacy of Complete Remission Patients with R/R Diffuse Large B-Cell Lymphoma After CAR-T Therapy: BTK Inhibitor Maintenance Treatment May Prolong Remission Duration

#PF952
Controlling Nutritional Status (CONUT) Score as a Prognostic Factor for Survival in CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma

#PF977
Safety and Efficacy of CAR-T Therapy in Autologous Stem Cell Transplantation-Failure B-Cell Non-Hodgkin Lymphoma Patients: A Retrospective Analysis

#PF1081
Optimized Conditioning Regimen Enhances TCRαβ⁺ Cell-Depleted Hematopoietic Stem Cell Transplantation Engraftment in Patients With Thalassemia Major

#PF1162
Autologous and Donor-Derived CD7-Knockout CD7-Targeted CAR T Therapy in Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia: A Phase 1/2 Clinical Study

#PF1318
Spectral Flow Cytometry-Guided Selection of Alternative Tumor-Associated Membrane Expression Antigens for CAR-T Cell Re-Treatment in Relapsed/Refractory B-Cell Malignancies

 

Published Abstracts

#PB2343
Combining Cytomorphology and Fluorescence In Situ Hybridization to Diagnose New Subtypes of Philadelphia Chromosome-Positive B-Acute Lymphoblastic Leukemia

#PB3204
CAR-T Treatment Strategy for B-Cell Lymphoma: High Complete Response Rate in M2 Macrophages and Granulocytes Deficiency Immune Microenvironment

#PB3483
The Role of Cerebrospinal Fluid Interleukin-6 in CAR T Cell-Associated Neurotoxicity

#PB3487
BKV Viremia Following CD7-CAR T Cell Therapy

#PB3494
Comparative Analysis of CD19 CAR T Cell Manufacturing and Pharmacokinetics in SLE and B-ALL Patients

# PB3651
Treatment and Nursing Care for a Severe AML Patient Undergoing a Second HSCT with a Large Area of Chronic Herpes Virus Infection on the Left Upper Limb

# PB3652
Parvovirus B19 with Fever/Rash Post Allo-HSCT: AML Case Report

No boundaries in medicine, no end to innovation.
In response to patients' urgent needs, the GoBroad medical team continues to integrate cutting-edge research with clinical care. Through evidence-based achievements and a forward-looking perspective, they strive to push the boundaries of treatment and bring hope for longer and better lives.